2010年，Hafezi教授被任命为日内瓦大学眼科诊所主任，直到2014年担任主席和全职教授。Hafezi自2012年起担任南加州大学(USC)凯克医学院洛杉矶分校的兼职教授，并于2015年开始担任Dietikon ELZA研究所的医学主任，以及苏黎世大学应用生物技术和分子医学中心眼细胞生物学研究小组的组长。2017年，他被任命为中国温州医科大学医学院客座教授。他也是国际角膜交联专家冬季会议大会主席，是国际圆锥角膜与交联专家夏季会议的共同主席。Hafezi被国际公认为角膜胶原交联术（corneal cross-linking, CXL）的先驱，将交联用于治疗圆锥角膜，并拓展了CXL原理的应用如治疗角膜感染等。Farhad Hafezi的研究围绕着角膜，它的生物力学，特别是角膜扩张，如圆锥角膜和激光屈光手术。Farhad Hafezi在同行评议的期刊上发表了170多篇文章，并在书中发表了18个章节，他的作品被引用了6900次。他的h指数是42，影响因子是590。

Prof. Hafezi was appointed to the University of Geneva as Chairman and Full Professor. Hafezi holds an adjunct professorship in Los Angeles at the Keck School of Medicine at the University of Southern California (USC) and he started as Medical Director of the ELZA Institute and as Group Leader of the Ocular Cell Biology research group the Centre for Applied Biotechnology and Molecular Medicine at the University of Zurich. Prof. Hafezi was made a Visiting Professor in the Faculty of Medicine at Wenzhou Medical University, Wenzhou, China. He has hosted International CXL Experts’ Meeting for many years as Chairman. He also serves as co-chairman in International Keratoconus and CXL Experts’ Summer Meeting. Hafezi is internationally recognized as a pioneer of corneal collagen cross-linking (CXL) for treating keratoconus and a pacemaker in translating CXL principles to new applications like infections. Farhad’s research revolves around the cornea, its biomechanics and, in particular, corneal ectasias like keratoconus and laser refractive surgery. With over 170 publications in peer-reviewed journals and 18 book chapters, Hafezi’s work has been cited 6,900 times. His h-index is 42 and his impact factor is 590.